Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma

• Published in: JGH open Vol. 4; no. 6; pp. 1135 - 1139
• Main Authors: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Msasahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
• Format: Journal Article
• Language: English
• Published: Melbourne Wiley Publishing Asia Pty Ltd 01.12.2020; John Wiley & Sons, Inc
• Subjects: Angiogenesis; Disease control; Growth factors; Hepatitis; hepatocellular carcinoma; Immunotherapy; lenvatinib; Liver cancer; Monoclonal antibodies; Original; Patients; ramucirumab; regorafenib; sorafenib; Targeted cancer therapy; Tumors; Japan; regorafenib; lenvatinib; sorafenib; ramucirumab; hepatocellular carcinoma
• ISSN: 2397-9070; 2397-9070
• DOI: 10.1002/jgh3.12408

Background and Aim Currently, there is no molecular‐targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u‐HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real‐world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u‐HCC after progression on treatment with LEN. Methods (Patients) and Results A total of 13 patients with u‐HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast‐enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3% (2/13) and 69.2% (9/13), respectively. According to RECIST, the ORR and DCR were 0% (0/13) and 69.2% (9/13), respectively. The median progression‐free survival was 4.1 months. The median albumin‐bilirubin scores did not deteriorate significantly at 4, 6, and 8 weeks after initiation of SOR, compared with the scores at the baseline. The most frequent grade 1 or 2 adverse events (AEs) were palmar–plantar erythrodysesthesia, fatigue, diarrhea, and hypertension. There was no incidence of grade 3 AEs. Conclusion Treatment with SOR may be effective for u‐HCC after failure on LEN and may not worsen the liver reserve. We demonstrated that treatment with sorafenib after lenvatinib failure could be useful for unresectable hepatocellular carcinoma. In addition, this treatment strategy may not worsen the liver reserve.